Protected: MAPS Publishes Ibogaine Investigator’s Brochure as a Free, Open-Access Resource
There is no excerpt because this is a protected post.
External link. We are not responsible for the content.
Read more ↗More From MAPS
MAPS Responds to Report of Progress for MDMA-assisted therapy for PTSD with FDA
August 10, 2026 — The non-profit Multidisciplinary Association for Psychedelic Studies (MAPS) today responded to an A...
Protected: 2026 Second Quarter — Policy & Advocacy Wrap Up
There is no excerpt because this is a protected post.
Psychedelic Science 2027 Speaker Submission Invites the Field to Bridge Promise and Practice
June, 25, 2026 — The Multidisciplinary Association for Psychedelic Studies (MAPS) announced the opening of speaker su...
Latest News
Veterans Affairs continues to drive federal psychedelics push; New FDA guidance; and Resilient Pharmaceuticals tries again for MDMA approval
Plus: Pharmaceutical giant Eli Lilly makes a psychedelics acquisition; Cardiovascular safety is top of mind for psych...
9 Questions I'm Obsessed With About Psychedelics Right Now
Welcome to The Psychedelic Blog. Bestselling essayist & Psychedelic cultural analyst examining how altered states sha...
Puerto Rico Makes Moves on Ibogaine, MDMA, and Psilocybin
The island's governor just signed an executive order effectively launching a pilot program to research psychedelic th...
Microdosing for Anxiety: What the Evidence Shows, and Where It Doesn’t
Microdosing for anxiety looks encouraging in open-label surveys and far less convincing under placebo control. What f...
The Toads Didn’t Consent to Being Milked, Sorry
Chasing "enlightenment" at the expense of desert toads is not the flex you think it is. [...] Read More... The post T...
Psychedelic Medicine Is Having an Identity Crisis — And That’s a Good Thing
For most of the last decade, the story of psychedelic medicine was a story about the trip itself. Guided sessions. Ey...